We are live on
!
Find out more
Winslow Capital Management Portfolio holdings
AUM
$25.6B
1-Year Est. Return
33.75%
This Fund
S&P 500
This Quarter
Est. Return
+18.2%
1 Year Est. Return
+33.75%
3 Year Est. Return
+154.66%
5 Year Est. Return
+213.06%
10 Year Est. Return
+1,176.99%
AUM
$26.5B
AUM Growth
+$2.45B
(+10%)
Cap. Flow
-$899M
Cap. Flow
% of AUM
-3.38%
Top 10 Holdings %
Top 10 Hldgs %
50.45%
Holding
65
New
6
Increased
11
Reduced
37
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adobe
ADBE
|
+$801M |
| 2 |
Booking.com
BKNG
|
+$454M |
| 3 |
Intuit
INTU
|
+$426M |
| 4 |
Edwards Lifesciences
EW
|
+$425M |
| 5 |
Trane Technologies
TT
|
+$386M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$391M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$352M |
| 3 |
Workday
WDAY
|
+$324M |
| 4 |
Union Pacific
UNP
|
+$293M |
| 5 |
DexCom
DXCM
|
+$291M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 46.56% |
| 2 | Consumer Discretionary | 15.96% |
| 3 | Healthcare | 12.1% |
| 4 | Communication Services | 11.96% |
| 5 | Financials | 5.65% |
Similar funds
UIM
VAI
KK
Winslow Capital Management's Q1 2024 Portfolio in Review
As of Q1 2024, Winslow Capital Management held 65 positions worth $26.5B, up 10% from $24.1B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Winslow Capital Management withdrew a net $899M in Q1 2024, closing 8 positions and reducing 37 holdings. Its most notable exit was DexCom, an estimated $291M position sold in full.
By sector, the portfolio is most concentrated in Technology at 47% of assets, up from 45% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Winslow Capital Management opened a new position in Booking.com worth $463M.
- Winslow Capital Management's largest Q1 2024 buy was Booking.com: 3,188,500 shares worth $463M.
- Winslow Capital Management added most to Adobe in Q1 2024, an estimated $801M increase.
- Winslow Capital Management's biggest Q1 2024 reduction was Vertex Pharmaceuticals, cutting an estimated $391M.
- Winslow Capital Management fully exited DexCom in Q1 2024, selling an estimated $291M.
- Winslow Capital Management's ten largest holdings make up 50% of its $26.5B portfolio in Q1 2024.
- Winslow Capital Management opened 6 new positions and closed 8 in Q1 2024.
- Winslow Capital Management's portfolio value rose 10% quarter-over-quarter to $26.5B.
Based on Winslow Capital Management's 13F filing for Q1 2024, filed 14 May 2024.